hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-28. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
== "4-4-3-2" balanced diet message == An integral and ubiquitous part of the program's message was the "4-4-3-2" balanced diet program, part of the standard USDA nutrition guidelines/recommendations promoted during the 1960s and 1970s. The use of dietary supplements was strongly discouraged; it was taught that all nutritional needs, including the proper intake of vitamins, minerals, fats and carbohydrates, could be adequately obtained solely by adhering to a balanced diet, with appropriate servings from the "basic four" food groups. This message was enthusiastically repeated by the children several times per episode. (The "basic four" food groups were updated by USDA in subsequent decades by the 1990s-era "Food Guide Pyramid", the later "MyPlate" and current (as of 2026) "New Pyramid" nutritional guidelines programs.)
Globally, about 2 percent of soybean meal is used for soy flour and other products for human consumption. Soy flour is used to make some soy milks and textured vegetable protein products, and is marketed as full-fat, low-fat, defatted, and lecithinated types.
Though the character originally was not meant to return in the season, Aya Cash reprised her role as Stormfront with a guest appearance in the first two episodes of the season. Kripke admitted that he took the decision to bring the character back even with a small role and that even Cash was unaware of her return for the season. Antony Starr admitted that he enjoyed working with Cash once again: "We've become really tight friends after doing season 2 together. To have her back, even just for a couple of days, was just great. She's sorely missed, but she will be forever remembered in season 3, jacking off Homelander." Charlize Theron made a surprise cameo appearance as Stormfront in the season's premiere for the trailer of the in-universe fictional film Dawn of the Seven, in the same vein as her appearance in the Marvel Cinematic Universe film Doctor Strange in the Multiverse of Madness as Clea. Paul Reiser also makes an appearance in the series as The Legend, a spoof of legendary screenwriter and producer Robert Evans whereas his comics counterpart was based on Stan Lee. Kumail Nanjiani reprised his role as Vik from The Boys Presents: Diabolical in "Herogasm". Voice actor Eric Bauza voiced Buster Beaver, the mascot of Buster Beaver Pizza and a parody of Chuck E. Cheese, while the animation was provided by 6 Point Harness, Bauza's former animation workplace.
=== Asexual === All known cnidarians can reproduce asexually by various means, in addition to regenerating after being fragmented. Hydrozoan polyps only bud, while the medusae of some hydrozoans can divide down the middle. Scyphozoan polyps can both bud and split down the middle. In addition to both of these methods, Anthozoa can split horizontally just above the base. Asexual reproduction makes the daughter cnidarian a clone of the adult. The ability of cnidarians to asexually reproduce ensures a greater number of mature medusa that can mature to reproduce sexually.
=== Setting === Opposing Force is set in the same location and timeframe as that of Half-Life, taking place at a remote New Mexico laboratory called the Black Mesa Research Facility. In Half-Life, the player takes on the role of Gordon Freeman, a scientist involved in an accident that opens an interdimensional portal to the borderworld of Xen, allowing the alien creatures of Xen to attack the facility. The player controls Freeman in an attempt to escape the facility and close the portal, ultimately traveling to Xen to do so. Opposing Force, however, shows the events of Half-Life from the perspective of a different protagonist. The player assumes the role of Adrian Shephard, a U.S. Marine Corps Corporal assigned to the Hazardous Environment Combat Unit, a specialized unit sent in to Black Mesa by the government to quell the alien threat and silence all witnesses. However, after Shephard becomes isolated from his fellow Marines, he must ally with the Black Mesa personnel and attempt to escape the base.
Sources: en.wikipedia.org
The amylin receptors (AMYRs) are a family of 3 receptors that are activated by amylin, a peptide hormone secreted together with insulin. They are each composed of a copy of the calcitonin receptor (CTR) bound to a receptor activity-modifying protein (RAMP), forming a heterodimer. They consist of AMY1 (RAMP1 with CTR), AMY2 (RAMP2 with CTR), and AMY3 (RAMP3 with CTR). Activation of these receptors appears to have a number of effects on eating behavior, including triggering feelings of satiation, reducing food intake, decreasing fat storage, and increasing energy usage. These effects have led to research into targeting these receptors with treatments for metabolic diseases and obesity. The amylin receptors are G protein-coupled receptor of the secretin receptor family. Consistent with their calcitonin receptor subunit, they appear to activate Gs alpha subunit pathways, and there have also been reports of Gq alpha subunit coupling. However, methodological difficulties related to amylin’s ability to bind with the calcitonin receptor have led some researchers to express uncertainty about these results.
=== Contraindications === Ceftriaxone should not be used in those with an allergy to ceftriaxone or any component of the formulation. Although there is negligible cross-reactivity between penicillins and third-generation cephalosporins, caution should still be used when using ceftriaxone in penicillin-sensitive patients. Caution should be used in people who have had previous severe penicillin allergies. It should not be used in hyperbilirubinemic neonates, particularly those who are premature because ceftriaxone is reported to displace bilirubin from albumin binding sites, potentially causing bilirubin encephalopathy. Concomitant use with intravenous calcium-containing solutions/products in neonates (≤28 days) is contraindicated even if administered through different infusion lines due to rare fatal cases of calcium-ceftriaxone precipitations in neonatal lungs and kidneys.
== Inhibitors == Glycogen synthase kinase inhibitors are different chemotypes and have variable mechanisms of action; they may be cations, from natural sources, synthetic ATP and non-ATP competitive inhibitors and substrate-competitive inhibitors. GSK3 is a bi-lobar architecture with N-terminal and C-terminal, the N-terminal is responsible for ATP binding and C-terminal which is called as activation loop mediates the kinase activity, Tyrosine located at the C-terminal it essential for full GSK3 activity.
So, in February 1807, Petar I planned an invasion of Herzegovina by Montenegrin forces and asked for Karađorđe's aid, wanting to connect the territory occupied by the Serbian rebel forces and Montenegro, which succeeded after the Battle of Suvodol in 1809. This support of Montenegro for the Serbs was reinforced due to the fact that in the war of 1806–1812, Ottoman troops, supported by French detachments on Illyria, attacked Montenegro along the entire border, and the Montenegrins did not have time to repel all the attacks. However, they managed to force the French troops to withdraw from Dubrovnik and conquered the Bay of Kotor. Napoleon himself offered Petar I the title "Patriarch of the entire Serbian nation or of the entire Illyricum" on the condition that he cease cooperation with Russia and accept a French protectorate, which he refused for fear of an eventual papal status jurisdiction or an Anti-clerical policy. However, the Treaty of Tilsit between France and Russia against the Ottomans helped put a stop to hostilities in the Balkans, with a truce taking place (which was perceived extremely negatively in Serbia, despite the fact that the truce did not apply to the Serb rebels). Also, there was a secret clause that provided for the division of Turkish possessions in the Balkans between Russia and France and the cancellation of the Slaveno-Serb empire project.
The ancient Greek and Roman philosophers and physicians associated old age with increasing dementia. It was not until 1901 that German psychiatrist Alois Alzheimer identified the first case of what became known as Alzheimer's disease, named after him, in a fifty-year-old woman he called Auguste D. He followed her case until she died in 1906, when he first reported publicly on it. During the next five years, eleven similar cases were reported in the medical literature, some of them already using the term Alzheimer's disease. The disease was first described as a distinctive disease by Emil Kraepelin after suppressing some of the clinical (delusions and hallucinations) and pathological features (arteriosclerotic changes) contained in the original report of Auguste D. He included Alzheimer's disease, also named presenile dementia by Kraepelin, as a subtype of senile dementia in the eighth edition of his Textbook of Psychiatry, published on 15 July 1910. For most of the 20th century, the diagnosis of Alzheimer's disease was reserved for individuals between the ages of 45 and 65 who developed symptoms of dementia. The terminology changed after 1977 when a conference on Alzheimer's disease concluded that the clinical and pathological manifestations of presenile and senile dementia were almost identical, although the authors also added that this did not rule out the possibility that they had different causes. This eventually led to the diagnosis of Alzheimer's disease independent of age.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.